PURPOSE: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. PATIENTS AND METHODS: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. RESULTS: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001). CONCLUSION: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples.
PURPOSE: Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. PATIENTS AND METHODS: A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. RESULTS: The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001). CONCLUSION: This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples.
Authors: Donna Niedzwiecki; Wendy L Frankel; Alan P Venook; Xing Ye; Paula N Friedman; Richard M Goldberg; Robert J Mayer; Thomas Anthony Colacchio; Jude Marie Mulligan; Timothy S Davison; Eamonn O'Brien; Peter Kerr; Patrick G Johnston; Richard D Kennedy; D Paul Harkin; Richard L Schilsky; Monica M Bertagnolli; Robert S Warren; Federico Innocenti Journal: J Clin Oncol Date: 2016-07-18 Impact factor: 44.544
Authors: Svitlana Tyekucheva; Neil E Martin; Edward C Stack; Wei Wei; Vinod Vathipadiekal; Levi Waldron; Michelangelo Fiorentino; Rosina T Lis; Meir J Stampfer; Massimo Loda; Giovanni Parmigiani; Lorelei A Mucci; Michael Birrer Journal: J Mol Diagn Date: 2015-04-30 Impact factor: 5.568